Results 51 to 60 of about 85,787 (336)

New Biomarker Identified for PDAC [PDF]

Cancer Discovery, 2017
Abstract A new study suggests that the protein THBS2 could lead to early detection of pancreatic ductal adenocarcinoma. By testing for THBS2 and another marker, CA19-9, researchers identified blood samples from patients with the disease with 98% specificity and 87% sensitivity.
openaire   +2 more sources

RelA regulates CXCL1/CXCR2-dependent oncogene-induced senescence in murine Kras-driven pancreatic carcinogenesis [PDF]

, 2016
Tumor suppression that is mediated by oncogene-induced senescence (OIS) is considered to function as a safeguard during development of pancreatic ductal adenocarcinoma (PDAC). However, the mechanisms that regulate OIS in PDAC are poorly understood. Here,
Algül, Hana, Demir, Ihsan Ekin, Diakopoulos, Kalliope Nina, Einwächter, Henrik, Heikenwälder, Mathias, Kehl, Timo, Korneeva, Olga, Lesina, Marina, Morton, Jennifer, Sansom, Owen J., Saur, Dieter, Schmid, Roland Michael, Sipos, Bence, Sperveslage, Jan, Steiner, Jörg Manfred, Wang, Timothy Cragin, Wimmer, Margit, Wörmann, Sonja Maria   +17 more
core   +1 more source

SerpinB2 regulates stromal remodelling and local invasion in pancreatic cancer [PDF]

, 2017
Pancreatic cancer has a devastating prognosis, with an overall 5-year survival rate of ~8%, restricted treatment options and characteristic molecular heterogeneity.
A H Allam, A Neesse, A Neesse, A V Biankin, A Xue, AB Seymour, AD Rhim, AK Witkiewicz, AM LeBeau, AR Shekouh, AV Biankin, B Hinz, BC Ozdemir, BJ Cochran, BJ Cochran, C Gaggioli, C Vennin, D Croucher, D Goldstein, D Herrmann, D Herrmann, D Mahadevan, D N Saunders, D Telgenhoff, DD Von Hoff, DR Croucher, DR Croucher, E Cerami, F Al-Ejeh, G Finak, H Shiomi, HW Smith, I Garrido-Laguna, J Condeelis, J Gao, J Gore, J Lee, J Li, J P Morton, J R W Conway, JA Lee, JJ Lee, JP Morton, K Kessenbrock, K L Vine, L Harris, M C Lucas, M J Cowley, M Nobis, M Pajic, M Pinese, M Ranson, MJ Duffy, ML Nyström, N L E Harris, N Waddell, P Bailey, P Carmeliet, P Timpson, P Timpson, R Cicchi, R F Shearer, R Kalluri, R Smith, RF Shearer, RG Rowe, RL Siegel, S Nurmenniemi, S Ulisse, SC Barry, SR Hingorani, SR Hingorani, TK Stutchbury, WA Schroder, Y Takeuchi, ZS Boyd, Ö Babur   +76 more
core   +1 more source

microRNAs: Novel regulators of the TGF-β pathway in pancreatic ductal adenocarcinoma

Molecular & Cellular Oncology, 2018
We identified that transforming growth factor-β (TGF-β) induces long non-coding RNA (lncRNA) MIR100HG along with its host microRNAs (miRNAs) miR-100 and miR-125b, to regulate its response in pancreatic ductal adenocarcinoma (PDAC).
Silvia Ottaviani, Leandro Castellano
doaj   +1 more source

The Role of Autophagy in Pancreatic Cancer—Recent Advances

Biology, 2019
Pancreatic ductal adenocarcinoma (PDAC) remains one of the deadliest cancers with a 5-year survival rate of only 9%, despite ongoing efforts to improve treatment.
Maria New, Sharon Tooze
doaj   +1 more source

Early Diagnosis of Pancreatic Ductal Adenocarcinoma by Combining Relative Expression Orderings With Machine-Learning Method

Frontiers in Cell and Developmental Biology, 2020
Pancreatic ductal adenocarcinoma (PDAC) is an aggressive and lethal cancer deeply affecting human health. Diagnosing early-stage PDAC is the key point to PDAC patients’ survival. However, the biomarkers for diagnosing early PDAC are inexact in most cases.
Zi-Mei Zhang, Jia-Shu Wang, Hasan Zulfiqar, Hao Lv, Fu-Ying Dao, Hao Lin   +5 more
doaj   +1 more source

Biological Hallmarks and New Therapeutic Approaches for the Treatment of PDAC

Life, 2021
Pancreatic Ductal Adenocarcinoma (PDAC) is one of the deadliest solid tumors and is estimated to become a leading cause of cancer-related death in coming years.
G. Digiacomo, Francesco Volta, I. Garajová, R. Balsano, A. Cavazzoni   +4 more
semanticscholar   +1 more source

Germline and Somatic DNA Damage Repair Gene Mutations and Overall Survival in Metastatic Pancreatic Adenocarcinoma Patients Treated with FOLFIRINOX [PDF]

, 2018
Purpose: Pancreatic ductal adenocarcinoma (PDAC) is a lethal cancer with lack of predictive biomarkers. We conducted a study to assess DNA damage repair (DDR) gene mutations as a predictive biomarker in PDAC patients treated with FOLFIRINOX ...
Gbolahan, Olumide, Hancock, Brad A., O'Neil, Bert H., Radovich, Milan, Sehdev, Amikar, Shahda, Safi, Stanley, Melissa, Wan, Jun, Wu, Howard H.   +8 more
core   +1 more source

Intratumoral bacteria may elicit chemoresistance by metabolizing anticancer agents

Molecular & Cellular Oncology, 2018
We recently reported that bacteria can be found within pancreatic ductal adenocarcinoma (PDAC) tumors. Some of these bacteria can metabolize and thereby inactivate the nucleoside analog gemcitabine.
Leore T. Geller, Ravid Straussman
doaj   +1 more source

Clinical and molecular characterization of HER2 amplified-pancreatic cancer [PDF]

, 2013
<p>Background: Pancreatic cancer is one of the most lethal and molecularly diverse malignancies. Repurposing of therapeutics that target specific molecular mechanisms in different disease types offers potential for rapid improvements in outcome ...
Biankin, A.V., Chang, D.K., Chantrill, L., Chin, V., Chou, A., Cowley, M.J., Gill, A.J., Goldstein, D., Grimmond, S.M., Humphris, J., Johns, A.L., Kassahn, K.S., Mead, R., Miller, D.K., Morey, A.L., Musgrove, E.A., Nagrial, A.M., Nones, K., Pajic, M., Patch, A.M., Pearson, J.V., Pinese, M., Rooman, I., Samra, J.S., Toon, C.W., Waddell, N., Wasan, H., Wu, J.   +27 more
core   +3 more sources